BCRA poster at ECP 2024

BRCA1/2 testing can inform which prostate cancer patients might respond to PARP inhibitors (PARPi). Having a better understanding of BRCA1/2 testing practices in the real-world setting can provide valuable insights into identifying gaps and opportunities to improve the identification of metastatic prostate cancer (mPC) patients who may benefit from PARPi treatment. In this study we investigated NGS testing practices results across specific European countries.

Read The Poster Now

First Name

Last Name

Institution

Job Title

Area of Interest

Country

State

Province

Comments

Privacy Policy I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. View our Privacy Policy for more information.

Pardot Opt-in I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

Comments